文献速递甲状腺核医学核素与放射性配体治疗

利用单时间点图像将给药的放射性碘活度(MBq)与处方病灶吸收剂量(cGy)关联:一种用于管理分化良好的甲状腺癌患者的基于回归的预测区间工具

The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-12

本研究纳入21例转移性分化型甲状腺癌患者的208个病灶,在给予222 MBq NaI-124I后24、48、72、120小时行定量PET,用广义估计方程建立单时间点生物标志物(如48小时SUVmax)与病灶吸收剂量的回归预测曲线及95%预测区间,并在接受131I治疗的169个病灶(15例患者)中验证。48小时SUVmax是病灶吸收剂量的最佳预测因子,可计算达到病灶阈值剂量2000 cGy所需的131I活度,但所选活度不得超过血液吸收剂量<2 Gy的最大耐受活度。

要点

  • 48小时SUVmax是预测病灶吸收剂量的最佳单时间点生物标志物。
  • 可利用预测曲线计算达到病灶阈值2000 cGy所需的131I活度及置信区间。
  • 所选活度不得超过血液吸收剂量<2 Gy的最大耐受活度(MTA)。

核心结论

  • 基于MIRD病灶吸收剂量估算和回归统计,报告了一种新的单时间点124I-PET剂量学生物标志物用于转移性分化型甲状腺癌患者放射性碘治疗的可行性。

研究设计与样本

  • 机构批准的方案纳入接受放射性碘治疗的转移性分化型甲状腺癌患者,共21例患者的208个SUVmax>1的病灶。
  • 给予222 MBq诊断性NaI-124I后,在24、48、72、120小时行定量PET扫描以确定单个病灶吸收剂量。
  • 使用广义估计方程生成最佳拟合回归线及95%预测区间的预测曲线,将单时间点候选生物标志物(如SUVmax、每克微居里活度)与预测病灶吸收剂量指标关联。

主要发现

  • 在接受131I治疗的169个病灶(15例患者)中,单个病灶cGy跨越3个数量级,中位数为22,000 cGy,证实病灶吸收剂量存在广泛异质性。
  • 对全部208个病灶的预测曲线初步分析证实,48小时SUVmax是病灶吸收剂量的最佳预测因子。
  • 该预测曲线可计算达到病灶阈值剂量2000 cGy所需的131I活度,并给出明确的置信区间。

关键数值与推荐

  • 病灶阈值吸收剂量为2000 cGy。
  • 最大耐受活度(MTA)定义为血液吸收剂量<2 Gy,为Memorial Sloan Kettering Cancer Center的标准治疗。
  • 预测曲线基于48小时单时间点124I-PET测量。

临床怎么用

  • 作者报告该方法为临床医生提供了一种工具,可基于单次48小时124I-PET测量,为选定的指标病灶选择个性化(精准)的治疗放射性活度(MBq)以达到目标病灶吸收剂量(cGy)。
  • 作者指出所选活度不得超过血液吸收剂量<2 Gy的最大耐受活度(MTA),这是Memorial Sloan Kettering Cancer Center的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To introduce a biomarker-based dosimetry method for the rational selection of a treatment activity for patients undergoing radioactive iodine 131I therapy (RAI) for metastatic differentiated thyroid cancer (mDTC) based on single-timepoint imaging of individual lesion uptake by 124I PET. METHODS: Patients referred for RAI therapy of mDTC were enrolled in institutionally approved protocols. A total of 208 mDTC lesions (in 21 patients) with SUVmax > 1 underwent quantitative PET scans at 24, 48, 72, and 120 h post-administration of 222 MBq of theranostic NaI-124I to determine the individual lesion radiation-absorbed dose. Using a general estimating equation, a prediction curve for biomarker development was generated in the form of a best-fit regression line and 95% prediction interval, correlating individual predicted lesion radiation dose metrics, with candidate biomarkers ("predictors") such as SUVmax and activity in microcurie per gram, from a single imaging timepoint. RESULTS: In the 169 lesions (in 15 patients) that received 131I therapy, individual lesion cGy varied over 3 logs with a median of 22,000 cGy, confirming wide heterogeneity of lesion radiation dose. Initial findings from the prediction curve on all 208 lesions confirmed that a 48-h SUVmax was the best predictor of lesion radiation dose and permitted calculation of the 131I activity required to achieve a lesional threshold radiation dose (2000 cGy) within defined confidence intervals. CONCLUSIONS: Based on MIRD lesion-absorbed dose estimates and regression statistics, we report on the feasibility of a new single-timepoint 124I-PET-based dosimetry biomarker for RAI in patients with mDTC. The approach provides clinicians with a tool to select personalized (precision) therapeutic administration of radioactivity (MBq) to achieve a desired target lesion-absorbed dose (cGy) for selected index lesions based on a single 48-h measurement 124I-PET image, provided the selected activity does not exceed the maximum tolerated activity (MTA) of < 2 Gy to blood, as is standard of care at Memorial Sloan Kettering Cancer Center. TRIAL REGISTRATION: NCT04462471, Registered July 8, 2020. NCT03647358, Registered Aug 27, 2018.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mauguen A, Grewal RK, Augensen F, et al. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37171634. doi:10.1007/s00259-023-06240-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。